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Background. Chronic graft versus host disease (cGVHD) is a complication following bonemarrow transplantation.The oral lesions
are difficult to control with a systemic pharmacological therapy. Case Description. A 63-year-old female patient, who underwent
an allogeniec transplantation for acute myeloid leukemia, developed a chronic oral and cutaneous GVHD.The patient was treated
with topical tacrolimus 0.1%, twice daily for twomonths, and underwent a protocol of oral hygiene characterized by 3 appointments
of scaling, root planning, and daily oral hygiene instructions. The patient showed marked resolution of gingival lesions and a
significant improvement of related pain and gingival inflammatory indexes. Clinical Implications. This case report suggests that
treatment with topical tacrolimus and professional oral hygiene may be helpful in the management of chronic oral GVHD with
severe gingival involvement.
1. Introduction
Chronic graft versus host disease (cGVHD) is a complication
following bone marrow transplantation, which frequently
involves the oral mucosa [1]. When affected, oral tissues
present with lichenoid-like lesions, erythema, and ulcera-
tions; lesions on gingiva can induce a “desquamative gingivi-
tis,” similar to that of oral lichen planus and mucous mem-
brane pemphigoid, presenting with epithelial desquamation,
erythematous zones, and erosive lesions on the gingival tis-
sue. Patients usually complain of pain and difficulty in eating,
speaking in and swallowing, with a significant decrease in
the quality of life. Oral hygiene is particularly difficult and
the periodontal status often worsens [2].
Tacrolimus is a macrolide immunosuppressant derived
from Streptomyces tsukubaensis. It is a relatively selective
inhibitor of calcineurin and it was initially developed as a
systemic agent to lessen allograft rejection [3, 4].
Previous reports suggest that topical therapy with tacrol-
imus can be helpful in the management of oral lesions caused
by GVHD [5–7]. In some of those patients, however, the
response on gingival lesions is often partial. We report a case
in which the combined treatment of topical tacrolimus and
periodontal therapy allowed satisfactory control of the severe
gingival profile due to oral cGVHD.
2. Case Presentation
A 63-year-old female patient, who underwent an allogeneic
transplantation for acute myeloid leukemia about 5 years ago,
with a complete clinical remission, presented with chronic,
biopsy proven, oral, and cutaneous GVDH of moderate
degree.The patient was referred to the Unit of Oral Medicine
Section of the University of Turin (Italy), complaining of
extreme gingival pain. Oral manifestations were character-
ized by atrophic and erosive lichenoid-like lesions on buccal
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Figure 1: Sixty-three-year-old female patient with gingival and buccal cGVHD at baseline ((a), (b)), and after the proposed protocol ((c),
(d)).
and gingival mucosa. Even if an immunosuppressive therapy
with systemic cyclosporine (Sandimmun Neoral, Novartis
Farma S.p.A., Origgio, Varese, Italy) and systemic prednisone
(Deltacortene, Bruno Farmaceutici S.p.A., Roma, Italy) was
carried out, the management of the oral disease was unsuc-
cessful.The patient complained of severe intraoral symptoms,
which made chewing, speaking, and oral hygiene procedures
very difficult.
Patient was informed about the experimental protocol
and signed a consent form. The ethics review board of the
Lingotto Dental School approved the study. She received
a comprehensive periodontal examination at baseline visit,
including full mouth plaque scores (FMPS) and full mouth
bleeding on probing scores (FMBS).We started the treatment
with tacrolimus ointment (Protopic 0.1% ointment, Astellas
Pharma S.p.A, Carugate, Milano, Italy) twice daily for two
months. Patient was carefully instructed on how to apply
the medications: finger rub application on dried lesions after
meals without eating, drinking, or speaking for at least half an
hour afterwards. Antimycotic treatment was also added, con-
sisting of miconazole gel (Daktarin 2% oral gel, Janssen-Cilag
S.p.A., Cologno Monzese, Milano, Italy) applied once daily
plus 0.12% chlorhexidine mouth rinse without alcohol
(Curasept A.D.S. 0.12%, Curaden Healthcare S.r.l., Saronno,
Varese, Italy) three times daily. In order to evaluate possible
systemic absorption, blood tacrolimus levels were monitored
at the beginning and at the end of the two-month protocol.
After 2 weeks from the beginning of therapy, she also received
a nonsurgical periodontal protocol, including oral hygiene
instructions and supra- and subgingival scaling as required.
Oral hygiene instructions were given by an experienced
dental hygienist, who also provided thorough supragingival
scaling and polishing with removal of all deposits and
staining, once a week, for three weeks [8]. Patient-related
outcomes included pain perception assessed at each visit by
Visual Analogue Scale (VAS). The VAS consisted of a 10 cm
horizontal linemarkedwith 0 (= no pain) to 10 (=most severe
pain experienced). At each visit, the patient was examined
by means of record chart compilation, oral examination, reg-
istration of symptoms and clinical sings, and periodontal
index.
The patient, at the end of the protocol, showed marked
resolution of gingival lesions and a significant improvement
of buccal lesions (Figure 1). No increase of tacrolimus plasma
levels was noticed during the treatment period. A reduction
in FMBS, FMPS, and VAS scores was observed (data not
shown). No reported complications or therapy side effects
were observed.
3. Discussion
The pathogenesis of plaque-related periodontal disease
involves local activation of the immune system induced by
bacterial factors . cGVHD is an immunomediated disease [1];
we can postulate that some influences could exist and that
a bacterial induced inflammation could amplify the effects
of cGVHD on gingival mucosa. Furthermore, dental plaque
may aggravate burning sensation and reported symptoms.
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Despite its limitations, our data proposes that treatment with
topical tacrolimus, combined with nonsurgical periodontal
therapy and oral hygiene instructions, may be successful
in reducing clinical gingival inflammation and improving
patient-related outcomes in a case of cGVHDwith severe gin-
gival involvement.We postulate that the topical drug is useful
in creating a preliminary breakdown in inflammation and
so allowing an efficient nonsurgical periodontal therapy con-
sisting of scaling and effective bacterial plaque control, which
can later represent an essential approach for the control
of gingival lesions and permit competent oral hygiene.
Topical tacrolimus is safe for short periods, but the systemic
absorption should, however, be monitored [10].
To the best of our knowledge, this is the first case ever
reported of a patient with gingival cGVHD treated with
nonsurgical periodontal therapy combined with topical
tacrolimus. Previously, topical tacrolimus has been success-
fully used for the treatment of oral cGVHD alone [6, 11, 12]
or in combination with systemic steroid [7] or photopheresis
[13]. The gingival involvement was detailed by Sa´nchez and
coworkers [5], who reported a successful treatment with
topical tacrolimus three times daily.
The importance of a careful plaque removal and the
maintenance of periodontal health are unequivocal for many
chronic diseases that can induce a desquamative gingivitis,
as oral lichen planus or pemphigoid [8]. Probably something
similar can happen for cGVHD too.
Systemic calcineurin inhibitors have been shown to have
oncogenic properties mainly linked to the production of
cytokines that promote tumour growth, metastasis, and angi-
ogenesis. To date there is no strong evidence that topical
application of calcineurin inhibitors may be associated with
an increased risk of tumours [4]. However, the benefits of
tacrolimus should be weighed against its potential risks, and
diligent long-term follow-up should be carried out by well-
trained oral clinicians.
The positive clinical results obtained with a standard pro-
fessional oral hygiene and nonsurgical periodontal protocol
could serve as a basis for recommending this as a first line
therapeutic intervention, especially in patients with pure gin-
gival involvement, in order to decrease gingival inflammation
and related pain and help affected patients in maintaining a
good oral hygiene. Studies on large groups of patients are,
however, suggested.
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